Grant Henderson and Lynda Menard of Vernal Biosciences discuss the CDMO’s concerted quality-by-design (QbD) approach for manufacturing mRNA therapeutics, ensuring that quality is designed into early process development to facilitate later transitions to high-quality GMP manufacturing at larger scale.
.svg)
